A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with ...

In separate, live virtual events, Alvaro Jose Alencar, MD, and Michael E. Williams, MD, discussed third-line options for a patient with relapsed/refractory chronic lymphocytic leukemia (CLL). CASE ...

Martin Dreyling, MD, University Hospital LMU Munich, in Germany, discusses the final follow-up results of the TRIANGLE study ...

In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed ...

On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...

During a Case-Based Roundtable® event, Hira Shaikh, MD, and participants discussed how they would treat a patient with ...

The FDA has approved tislelizumab plus chemotherapy for the treatment of patients with newly diagnosed, locally advanced or ...

Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

Sanjay K. Juneja, MD, hematologist & medical oncologist at Mary Bird Perkins Cancer Center, discusses how artificial ...

Jacob E. Berchuck, MD, discusses how a new epigenomic platform may influence the accessibility of PSMA-based therapies, especially for patients who may not have easy access to PSMA PET scans.